Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab in Primary Sjögren's Syndrome
NCT02291029Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of iscalimab in primary Sjögren's syndrome (6 cohorts), sponsored by Novartis. Primary endpoint: EULAR Sjögren's Syndrome Disease Activity Index at 12 weeks. Started Oct 2014; status: completed.
02
Drugs
iscalimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02291029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291029.